$XOMA News

Last published 4mo ago

4mo agoXOMA XOMAO XOMAP LGNDXOMA Royalty Announces Closing of Its Acquisition by LigandGlobeNewswireEMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty.
5mo agoXOMA XOMAO XOMAPXOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record DateGlobeNewswireEMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash dividends to holders
6mo agoLGND XOMALigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorGlobeNewswireTransaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across
8mo agoXOMA XOMAO XOMAPXOMA Royalty to Present at Investor Conferences in MarchGlobeNewswireEMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor
9mo agoGBIO XOMA XOMAO XOMAPXOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.GlobeNewswireEMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies
10mo agoXOMA XOMAO XOMAPXOMA Royalty Announces CFO TransitionGlobeNewswireEMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA
10mo agoXOMA XOMAO XOMAPXOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for MezagitamabGlobeNewswire– Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage
10mo agoXOMA XOMAO XOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to
11mo agoGBIO XOMAXOMA Royalty Enters into Agreement to Acquire Generation BioGlobeNewswire- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for
11mo agoMURA XOMA XOMAO XOMAPXOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plcGlobeNewswireEMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced
11mo agoMURA XOMAMural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionGlobeNewswireWALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the
11mo agoMURA XOMAMural Oncology Announces Sanction of the Scheme by the High CourtGlobeNewswireWALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its
11mo agoMURA XOMAMural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyGlobeNewswireWALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty
11mo agoLVTX XOMA XOMAO XOMAPXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.GlobeNewswireEMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding
12mo agoXOMA XOMAO XOMAPXOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsGlobeNewswireBusiness development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty's
1y agoLVTX XOMALAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA
1y agoMURA XOMAMural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA RoyaltyGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION WALTHAM, Mass.
1y agoLVTX XOMA XOMAO XOMAPXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase AgreementGlobeNewswire- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and
1y agoLVTX XOMA XOMAO XOMAPXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.GlobeNewswireEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today
1y agoEPIX XOMAESSA Pharma Inc. Amends Agreement with XenoTherapeuticsPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has reached an agreement to amend its previously announced...
1y agoMURA XOMAMural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General MeetingGlobeNewswireWALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural"), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel
1y agoXOMA XOMAO XOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and
1y agoHLVX XOMA XOMAO XOMAPXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.GlobeNewswireEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech
1y agoXOMA XOMAO XOMAPXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireEMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer,
1y agoMURA XOMAMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareGlobeNewswireWALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation
1y agoXOMA XOMAO XOMAPXOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsGlobeNewswireBusiness development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently
1y agoTSBX XOMA XOMAO XOMAPXOMA Royalty Announces Closing of Tender Offer for Turnstone BiologicsGlobeNewswire- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a
1y agoLVTX XOMA XOMAO XOMAPXOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced
1y agoHLVX XOMA XOMAO XOMAPHilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value RightGlobeNewswireBOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered
1y agoEPIX XOMAESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination ...
1y agoTSBX XOMA XOMAO XOMAPTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced
1y agoXOMA XOMAO XOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and
1y agoXOMA XOMAO XOMAPXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 MillionGlobeNewswireEMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a
1y agoXOMA XOMAO XOMAPXOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business AchievementsGlobeNewswirePipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen's tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase
1y agoXOMA XOMAO XOMAPXOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceGlobeNewswireEMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad
1y agoXOMA XOMAO XOMAPXOMA Royalty Completes Sale of Kinnate Pipeline AssetsGlobeNewswireXOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens
1y agoXOMA XOMAO XOMAPXOMA Royalty to Present at Jones Healthcare and Technology Innovation ConferenceGlobeNewswireEMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (("XOMA", NASDAQ:XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter
1y agoXOMA XOMAO XOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and
1y agoXOMA XOMAO XOMAPXOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business AchievementsGlobeNewswireDoubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day
1y agoLGND XOMALigand Leads $75 Million Royalty Financing in Castle Creek BiosciencesGlobeNewswireCapital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25
1y agoXOMA XOMAO XOMAPXOMA Royalty to Present at Investor Conferences in MarchGlobeNewswireEMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor
1y agoXOMA XOMAO XOMAPXOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireEMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th
1y agoXOMA XOMAO XOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series
1y agoXOMA XOMAO XOMAPXOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioGlobeNewswireSeralutinib becomes XOMA Royalty's seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by
2y agoXOMA XOMAO XOMAPXOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesGlobeNewswireZevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio of
2y agoXOMA XOMAO XOMAPXOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceGlobeNewswireXOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to
2y agoTWST XOMATwist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in CashBusiness WireTwist to retain all upfront, service and other revenue earned under antibody discovery and biopharma solutions agreements as well as half of future milestones and royalties Twist Bioscience Corporation (NASDAQ:TWST), a
2y agoXOMA XOMAO XOMAPZevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)GlobeNewswireMIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in
2y agoXOMA XOMAO XOMAPXOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswireEMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of
2y agoXOMA XOMAO XOMAPXOMA Royalty to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireEMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September